HYDERABAD, India — Dr. Reddy’s Laboratories has been cleared by a U.S. court to sell a generic version of sanofi-aventis’ Allegra D-24 allergy medication.
The India-based pharmaceutical company said late Sunday that the U.S. District Court of New Jersey on Jan. 28 lifted an earlier motion for a preliminary injunction and cleared Dr. Reddy’s to sell its fexofenadine hydrochloride/pseudoephedrine hydrochloride 180 mg/240 mg extended-release tablets.
Dr. Reddy’s reported that its generic product, which treats allergy symptoms and congestion, was approved by the Food and Drug Administration last March.
In addition, Dr. Reddy’s said that plaintiffs sanofi-aventis and Albany Molecular Research have been required to post a $40 million security with the court toward the possibility that the injunction had been wrongfully granted.
Dr. Reddy’s added that it aims to pursue an award of that security, saying that it has been prevented from launching the generic allergy drug since the court imposed the injunction last June.
